The mannose receptor (Cluster of Differentiation 206, CD206) is a C-type lectin primarily present on the surface of macrophages, immature dendritic cells and liver sinusoidal endothelial cells, but is also expressed on the surface of skin cells such as human dermal fibroblasts and keratinocytes. It is the first member of a family of endocytic receptors that includes Endo180 (CD280), M-type PLA2R, and DEC-205 (CD205).
The receptor recognises terminal mannose, N-acetylglucosamine and fucose residues on glycans attached to proteins found on the surface of some microorganisms, playing a role in both the innate and adaptive immune systems. Additional functions include clearance of glycoproteins from circulation, including sulphated glycoprotein hormones and glycoproteins released in response to pathological events. The mannose receptor recycles continuously between the plasma membrane and endosomal compartments in a clathrin-dependent manner.
The mannose receptor is a type I transmembrane protein, with an extracellular N-terminus and an intracellular C-terminus. It is first synthesised as an inactive precursor, but is proteolytically cleaved to its active form in the Golgi apparatus. In general, The extracellular portion of the receptor is composed of 8 consecutive C-type carbohydrate recognition domains (CRDs) closest to the plasma membrane, followed by a single fibronectin type II repeat domain and an N-terminal cysteine-rich domain. The cytoplasmic tail is not capable of signal transduction in isolation, since it lacks the appropriate signaling motifs.
The N-terminal cysteine-rich domain is homologous to the ricin B chain and binds to sulphated sugar moieties, with particularly high affinity for N-Acetylgalactosamine and galactose residues sulphated at positions 3 and 4 of their pyranose rings.
Other ligands include chondroitin sulfates A and B, as well as sulphated Lewisx and Lewisa structures. The mannose receptor is the only member of the family in which this domain is functional.
Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.
Un est un agent biologique pathogène responsable d'une maladie infectieuse. Les agents infectieux sont majoritairement des micro-organismes, notamment des bactéries et des virus. Cependant, certains agents pathogènes ne sont pas des organismes (les prions), d'autres ne sont pas microscopiques (les vers parasites). Le pouvoir pathogène d'un agent infectieux mesure sa capacité à provoquer une maladie chez un organisme hôte. La virulence d'un agent infectieux mesure sa capacité à se développer dans un organisme (pouvoir invasif) et à y sécréter des toxines (pouvoir toxique).
Explore les mécanismes de défense innés, y compris le système de complément, l'inflammation, l'immunité antivirale, la migration leucocytaire et les récepteurs de la phagocytose.
Explore le système immunitaire adaptatif, la production de lymphocytes, l'auto-tolérance, l'immunité humorale et cellulaire, et les rôles des anticorps et des protéines MHC.
Explique l'activation du système de complément et le rôle des molécules effectrices dans l'immunité innée, en se concentrant sur la lyse des agents pathogènes et la défense antivirale.
Cells have evolved endocytic pathways to internalize different molecules, to regulate intra-cellular communication and their interaction with external environment. Pathogens have co-evolved with cells to exploit these processes for infections. In particula ...
Cell-cell communication is fundamental for immune balance. Multivalent interactions of surface receptors at immune interfaces drive specific communication, with stimulatory and inhibitory signals guiding the immune outcome. Notably, the valency, affinity, ...
EPFL2023
Vaccine technology is still facing challenges regarding some infectious diseases, which can be addressed by innovative drug delivery systems. In particular, nanoparticle-based vaccines combined with new types of adjuvants are actively explored as a platfor ...